US drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew of multibillion dollar takeovers in the biopharma sector this year. AbbVie is stumping up more ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company's key schizophrenia drug, emraclidine, The Wall Street ...

Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...

Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of ...

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an opportunity for consumers interested in body contouring ...

The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). AbbVie: Financial Performance Dissected Market Capitalization Analysis: With a profound ...

AbbVie (NYSE: ABBV ) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

IRVINE, Calif., Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an ...

AbbVie ABBV underwent analysis by 17 analysts ... The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). Market Capitalization Analysis: With ...